Summary
The chronic administration of haloperidol to mice over periods of 1 week to 3 weeks has been shown not to decrease the anti-amphetamine properties of the compound, as measured by determining group toxicity and the inhibition of enhanced metabolic rate; on the other hand, the cataleptogenic effect of the drug slightly and transiently decreased after long-term treatment, the potentiation of pentobarbital narcosis being markedly reduced.
In rats, prolonged administration of haloperidol for 2 to 3 months failed to affect cataleptogenic activity, diminished the potentiating effect on pentobarbital narcosis, and had no influence on the inhibition of amphetamine-induced stereotypy. The inhibition of amphetamine hypermotility, however, exhibited a considerably altered pattern, developing much more slowly but increasing gradually.
The chronic administration of haloperidol has been shown to have no effect on brain noradrenaline and dopamine levels in either the mouse or the rat.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andén, N.-E., Dahlström, A., Fuxe, K., Hökfelt, T.: The effects of haloperidol and chlorpromazine on the amine levels of central monoamine neurons. Acta physiol. scand.68, 419–420 (1966).
—, Roos, B.-E., Werdinus, B.: Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum. Life Sci.3, 149–158 (1964).
Boissier, J. R., Pagny, J., Moulle, P., Forest, S.: Quelques actions pharmacologiques du haloperidol (R 1625). Acta neurol. belg.60, 39–53 (1960).
Carlsson, A., Lindqvist, M.: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta pharmacol. (Kbh.)20, 140–144 (1963).
Drujan, B. D., Sourkes, T. L., Layne, D. S., Murphy, G. F.: The differential determination of catecholamines in urine. Canad. J. Biochem.37, 1153–1159 (1959).
Himwich, W. A., Glisson, S. N.: Effect of haloperidol on caudate nucleus. Int. J. Neuropharmacol.6, 329–332 (1967).
Issekutz, B., Issekutz, B., Jr.: Einfache Apparate zur Messung des Sauerstoff-Verbrauches von Versuchstieren. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.199, 306–311 (1942).
Janssen, P. A. J.: Vergleichende pharmakologische Daten über sechs neue basische 4′-Fluorobutyrophenon-Derivate. Haloperidol, Haloanison, Triperidol, Methylperidid, Haloperidid und Dipiperon. Arzneimittel-Forsch.11, 819–924, 932–938 (1961).
Knoll, J., Vajnovszky, B.: Motimeter, a new sensitive apparatus for the quanttative measurement of hypermotility caused by psychostimulants. Arch. int. Pharmacodyn.130, 141–154 (1961).
Morpurgo, C.: Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction. Arch. int. Pharmacodyn.137, 84–90 (1962).
Da Prada, M., Pletscher, A.: Acceleration of the cerebral dopamine turnover by chlorpromazine. Experientia (Basel)22, 465 (1966).
Schelkunov, E. L.: Adrenergic effect of chronic administration of neuropleptics. Nature (Lond.)214, 1210–1212 (1967).
Sharman, D. F.: Changes in the metabolism of 3,4-dihydroxyphenylethylamine (dopamine) in the striatum of the mouse induced by drugs. Brit. J. Pharmacol.28, 153–163 (1966).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
György, L., Pfeifer, K.A. & Hajtman, B. Modification of certain central nervous effects of haloperidol during long-term treatment in the mouse and rat. Psychopharmacologia 16, 223–233 (1969). https://doi.org/10.1007/BF02456046
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02456046